Unlike earlier coverage that focused on headlines (Category 2 removals and the July 2026 PCAC meeting), this follow-up zeroes in on the practical realities that will determine what happens next: API supply chain compliance and enforcement risk
it cannot make a high dose appropriate for a low-substrate body, remove the heart-rate tail in a sensitive person, or guarantee anyone reaches 15 mg in real life
7 These reductions were not accompanied by systemic immunosuppression markers, suggesting local rather than systemic anti-inflammatory activity a profile more consistent with tissue-level NF-B pathway modulation than with global glucocorticoid-type immunosuppression
However, there are potential side effects, which are mild and temporary
Six domains clinical, commerce, CRM, AI engagement, targeting, and compliance sharing one PostgreSQL database